1. Home
  2. LTRX vs CLLS Comparison

LTRX vs CLLS Comparison

Compare LTRX & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lantronix Inc.

LTRX

Lantronix Inc.

N/A

Current Price

$7.06

Market Cap

328.9M

ML Signal

N/A

Logo Cellectis S.A.

CLLS

Cellectis S.A.

N/A

Current Price

$1.43

Market Cap

394.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LTRX
CLLS
Founded
1989
1999
Country
United States
France
Employees
N/A
N/A
Industry
Computer Communications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
328.9M
394.4M
IPO Year
2000
2014

Fundamental Metrics

Financial Performance
Metric
LTRX
CLLS
Price
$7.06
$1.43
Analyst Decision
Strong Buy
Buy
Analyst Count
6
5
Target Price
★ $10.58
$5.33
AVG Volume (30 Days)
★ 1.0M
171.9K
Earning Date
11-04-2026
11-06-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 65.52
N/A
EPS
N/A
★ N/A
Revenue
★ $120,899,000.00
N/A
Revenue This Year
$14.67
N/A
Revenue Next Year
$13.36
$10.70
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$4.37
$1.25
52 Week High
$8.75
$5.48

Technical Indicators

Market Signals
Indicator
LTRX
CLLS
Relative Strength Index (RSI) 72.88 26.03
Support Level $5.09 $1.31
Resistance Level $7.38 $3.47
Average True Range (ATR) 0.37 0.14
MACD 0.17 -0.01
Stochastic Oscillator 85.86 17.81

Price Performance

Historical Comparison
LTRX
CLLS

About LTRX Lantronix Inc.

Lantronix Inc is a networking company. It provides secure data access and management solutions for the Internet of Things (IoT) and information technology assets. It organizes its products and solutions into three product lines: Embedded IoT Solutions, IoT Systems Solutions, and Software and Services. The company operates in a single operating segment: the development, marketing, and sale of industrial and enterprise IoT products and services. The company serves a diverse range of markets including healthcare, industrial, security, energy, transportation, and government networking. Its primary geographic regions: the Americas; EMEA; and APJ. The Americas contribute the vast majority of total revenue.

About CLLS Cellectis S.A.

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Share on Social Networks: